Referenzen

More information about references found on this website.

 

  1. As a result of the merger in May 2013 between Intercell AG and Vivalis SA to form Valneva SE, the Company’s 2018 and 2013 results are not fully comparable. Vivalis SA’s results were fully included in the income statement of 2013 while Intercell’s results were only included for the seven-month period starting from June 2013
  2. Including service revenues and license fees
  3. As of December 31
  4. Valneva press release: https://www.valneva.com/en/investors-media/news/2019#4010
  5. Valneva press release: https://www.valneva.com/en/investors-media/news/2019#4014
  6. How many people get Lyme disease? | Lyme Disease | CDC. (n.d.). Retrieved from https://www.cdc.gov/lyme/stats/humancases.html
  7. Estimated from available national data. Number largely underestimated based on WHO Europe Lyme Report as case reporting is highly inconsistent in Europe and many LB infections go undiagnosed; ECDC tick-borne-diseases- meeting-report
  8. Stanek et al. 2012, The Lancet 379:461–473
  9. New Scientist, Lyme disease is set to explode and we still don’t have a vaccine; March 29, 2017, https://www.newscientist.com/article/mg23431195-800-lyme-disease-is-set-to-explode-and-you-cant-protect-yourself
  10. Valneva press release: https://www.valneva.com/en/investors-media/news/2018#303
  11. Valneva press release: https://www.valneva.com/en/investors-media/news/2018#282
  12. No differences in the safety profile were observed for the adjuvanted groups compared to the non-adjuvanted treatment groups
  13. IgG levels were substantially higher after three immunizations (Day 84) compared to after two (Day 56)
  14. Valneva press release: https://www.valneva.com/en/investors-media/news/2017#270
  15. Factsheet Chikungunya. Retrieved from https://www.paho.org/hq/index.php?option=com_content&view=article&id=8303:2013-hoja-informativa-chikungunya&Itemid=40023&lang=en
  16. PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas – EW 51 (December 22, 2017). Retrieved from https://www.paho.org/hq/dmdocuments/2017/2017-dec-22-phe-CHIKV-cases-ew-51.pdf
  17. Cardona-Ospina et al., Trans R Soc Trip Med Hyg 2015
  18. Valneva press release: https://www.valneva.com/en/investors-media/news/2019#305
  19. Valneva press release: https://www.valneva.com/en/investors-media/news/2018#304
  20. Hallengärd et al. 2013 J. Virology 88: 2858-2866
  21. Provisional Data as of January 2, 2019, https://www.cdc.gov/zika/reporting/case-counts.html
  22. Valneva press release: https://www.valneva.com/en/investors-media/news/2018#300
  23. Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
  24. Dubberke ER, Clinical Infectious Diseases 55, no. suppl 2 (2012): S88-S92.
  25. Magill S, Edwards J R, Bamberg W et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. New England Journal of Medicine 2014;370:1198-208
  26. Lessa et al, Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34
  27. Lessa et al, Clostridium difficile infection. N Engl J Med 2015;372:1539-48).